Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Chemically Assisted Capsulectomy-A New Clinical Approach

This study has been withdrawn prior to enrollment.
(preliminary analysis showed no difference)
Information provided by:
Vanderbilt University Identifier:
First received: September 23, 2008
Last updated: October 25, 2011
Last verified: October 2011

The purpose of this study is to make available an agent,Mesna, which can assist the surgeon during the procedure of capsulectomy.

Condition Intervention
Capsular Contracture
Drug: Mesna

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Chemically Assisted Capsulectomy-A New Clinical Approach

Resource links provided by NLM:

Further study details as provided by Vanderbilt University:

Primary Outcome Measures:
  • Evaluate the safety and efficacy of Mesna as an agent for chemically assisted capsulectomies [ Time Frame: one year ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • To compare capsular contracture rates between the control and the Mesna group one year after surgery [ Time Frame: one year ] [ Designated as safety issue: No ]

Enrollment: 20
Study Start Date: January 2005
Study Completion Date: December 2009
Primary Completion Date: August 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Standard procedure for removal of capsule; no mesna
Drug: Mesna
A. Mesna will be used to aid in the removal of the capsule when capsulectomy is performed
Experimental: A.
The use of Mesna of removal of capsule for capsular contracture.
Drug: Mesna
A. Mesna will be used to aid in the removal of the capsule when capsulectomy is performed

Detailed Description:

Mesna is a FDA approved drug for the treatment of respiratory diseases and is used a protective agent against drugs in oncology patients. It has also been used in Gynecologic surgery and ENT. Mesna is a drug that breaks down adhesions between tissue layers.


Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • All females undergoing capsulectomy

Exclusion Criteria:

  • All pregnant women and nursing mothers will be exclued
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00758667

Sponsors and Collaborators
Vanderbilt University
Principal Investigator: Bruce Shack, MD Vanderbit Unviersity Medical Center
  More Information

No publications provided

Responsible Party: R. Bruce Shack, MD, Vanderbilt University Identifier: NCT00758667     History of Changes
Other Study ID Numbers: 010518
Study First Received: September 23, 2008
Last Updated: October 25, 2011
Health Authority: United States: Institutional Review Board

Keywords provided by Vanderbilt University:
capsular contracture
Capsular contracture after breast implant placement

Additional relevant MeSH terms:
Joint Diseases
Muscular Diseases
Musculoskeletal Diseases
Pharmacologic Actions
Physiological Effects of Drugs
Protective Agents processed this record on November 25, 2014